

AQTUAL Rheumatoid Arthritis Treatment Selection Test

Bringing biological insight to RA therapy selection

The Clinical Challenge

Targeted therapies have significantly improved the management of rheumatoid arthritis (RA). However, predicting which patients will respond to a specific biologic or targeted synthetic DMARD remains challenging.

In the absence of reliable predictive biomarkers, healthcare providers often rely on a trial-and-error approach to drug selection, with patients cycling through multiple therapies before achieving disease control. During this time, patients may experience ongoing inflammation, disease progression, comorbidities, and reduced quality of life.

Flagship Test in Development

Aqtual is developing a blood-based clinical assay that analyzes molecular biomarkers in a patient's cell-free DNA (cfDNA) to predict response to commonly used RA therapies, including those targeting TNF, JAK, and T-cell co-stimulation pathways.

Test results are intended to be used with clinical judgment, patient preferences, and comorbidities to inform treatment selection. When successfully developed and validated, the assay will:

- Enable more personalized RA treatment decisions
- Increase patient confidence when switching therapies
- Provide additional biological context to support prior authorization requests


Intended Patient Population

- Adults with moderate to high RA disease activity
- Initiating a new or alternative biologic or targeted synthetic DMARD (b/tsDMARD)
- Applicable to both biologic-naïve and experienced patients


Clinical Development Progress

- Over 1,400 patients have been enrolled in a prospective clinical study (PRIMA-102).
- Assay development and validation activities are ongoing.

Proposed Clinical Workflow



The healthcare provider collects a whole blood sample and ships it at room temperature to the Aqtual central laboratory.



Aqtual analyzes cell-free DNA derived from regulatory active chromatin to assess biomarkers of RA therapy response.



The healthcare provider integrates the test result with clinical factors to inform therapy selection.

Interested in learning more, receiving updates, or participating in future research collaborations?



admin@aqtual.com
www.aqtual.com

Feb-2026